Targeting leftover leukemia cells with a combination therapy
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug combo (tagraxofusp, azacitidine, and venetoclax) for people with acute myeloid leukemia (AML) who have very small amounts of cancer cells still present after initial treatment. The goal is to see if it can clear these leftover cells and prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with acute myeloid leukemia (AML).
- Your leukemia is in remission (complete or partial) with less than 5% blast cells in your bone marrow.
- You have a very small amount of leftover leukemia cells (at least 0.1% detected by a special test).
- You are generally able to take care of yourself (ECOG score 0-2).
- Your liver, kidneys, and heart are working well enough based on recent blood tests and a heart scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called tagraxofusp combined with a gentle chemotherapy regimen for people whose acute myeloid leukemia (AML) has come back or not responded to an initial venetoclax-based treatment. The study focuses on patients whose leukemia cells have a protein called CD123 on their surface.
This trial tests a combination of three drugs (tagraxofusp, azacitidine, and venetoclax) for people newly diagnosed with a type of acute myeloid leukemia (AML) that has developed after treatment with certain prior drugs (hypomethylating agents). The goal is to see if this combination is safe and effective.
This trial tests a combination of drugs (azacitidine, venetoclax, and a liposome form of chemotherapy) to see if it can clear tiny amounts of remaining leukemia in people who are already in remission after their first treatment. It aims to prevent the leukemia from coming back.
This trial tests a combination of two drugs, azacitidine and venetoclax, for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells left (measurable residual disease). The goal is to see if this treatment can clear those remaining cells before a stem cell transplant.
This Phase 2 trial tests a combination of venetoclax, cladribine, low-dose cytarabine, and azacitidine in people with untreated acute myeloid leukemia (AML). It may help shrink the leukemia and improve blood counts by trying a stronger, multi-drug approach.
This trial tests a new combination of drugs for people with acute myeloid leukemia (AML) whose cancer did not respond to or stopped responding to the usual first-line treatment. The goal is to see if this new approach can help where the previous one didn't.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.